SARS-CoV-2 Spike-Protein Pseudotyped Lentiviral Particles

Since SARS and MERS coronaviruses are pathogenic, research on them requires bio-safety level-3 procedures, which can be difficult to carry out in commercial and university laboratories. An alternative approach is to pseudotype lentiviral particles with the coronavirus coat proteins. This enables researchers to carry out studies on these viral elements in S2 laboratories.

Lentiviral pseudotyping provides a scalable Biosafety Level 2-compatible (S2) method to test the key elements required for interacting with host receptors. This wider availability of reagents will accelerate critical research to enhance understanding of the biology of these viruses by facilitating studies such as:

• Screening compounds, antibodies, or other factors for inhibition or agonistic effects on spike protein binding.
• Testing mutational variants of the spike protein to see how they change binding efficacy.
• Identifying receptors or otherwise characterizing binding and potential pathogenicity of the novel SARS-CoV-2 coronavirus.

Nucleus Biotech is pleased to offer Cellecta´s range of spike-protein-pseudotyped lentiviral particles with fluorescent protein or luciferase reporters. You can obtain lentiviral particles pseudotyped with wildtype MERS CoV, SARS CoV, and SARS CoV-2 spike proteins as well as with the spike proteins from the emerging SARS CoV-2 variants of concern such as Delta, Alpha, Beta, and Gamma. Moreover, pseudotyped particles displaying the D614G spike protein mutant are also available.

In case you are interested in pseudotyped lentiviral particles for any Coronavirus spike protein not listed below, we can provide Cellecta´s custom preparation service – please contact us for a quotation.